UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/337,675	06/22/1999	RAJEEV A. JAIN	029318/0497	9275

31049 7590 11/17/2006

ELAN DRUG DELIVERY, INC.
C/O FOLEY & LARDNER LLP
3000 K STREET, N.W.
SUITE 500
WASHINGTON, DC 20007-5109

EXAMINER	
TRAN, SUSAN T	
ART UNIT	**PAPER NUMBER**
1615	

DATE MAILED: 11/17/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	09/337,675	JAIN ET AL.	
	Examiner	Art Unit	
	Susan T. Tran	1615	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *23 August 2006*.

2a)☒ This action is **FINAL**. 2b)☐ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) *1-22 and 25-54* is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5)☐ Claim(s) _____ is/are allowed.

6)☒ Claim(s) *1-22 and 25-54* is/are rejected.

7)☐ Claim(s) _____ is/are objected to.

8)☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.

10)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☐ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☐ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☐ Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date *09/07/06;10/16/06*.
4) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____.
5) ☐ Notice of Informal Patent Application
6) ☐ Other: _____.

DETAILED ACTION

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

> (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* **v.** *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 1-22 and 25-53 are rejected under 35 U.S.C. 103(a) as being unpatentable over Desieno et al. US 5,573,783 and Liversidge et al. US 5,145,684, in view of Fiend et al. US 5,811,388.

Desieno teaches a pharmaceutical film matrix comprising nanoparticles of a low solubility drug associated with a steric stabilizer (surface stabilizer), and over coated with a protective layer (abstract). Desieno also teaches the drug particles having extremely small effective average particle size can be prepared by wet milling in the presence of grinding media in conjunction with a surface modifier (column 2, lines 51-55). The effective average particle size is less than about 400 nm (column 6, lines 15-24). Suitable drug substances are disclosed in column 3, lines 16-46, which includes

naproxen and cyclosporin. The steric stabilizers are disclosed in column 3, lines 56-65, but the most preferred steric stabilizer is polyvinylpyrrolidone (column 4, lines 22-23). The protective layer over coated the film matrix comprises polyvinylpyrrolidone (PVP) and polyethylene glycol (PEG) (column 5, lines 1-13). Column 4, lines 42-67 discloses the process for preparing the nanoparticles, wherein water is used for the dissolution and suspensions steps is also disclosed. Examples 1 and 2 show the amounts of drug that falls within the claimed range.

It is noted that Desieno does not expressly teach the time period of controlled release from about 2 to about 24 hours. However, products of identical chemical composition cannot have mutually exclusive properties. A chemical composition and its properties are inseparable. Therefore, if the prior art teaches the identical chemical structure, the properties applicant discloses and/or claims are necessarily present. *In re Spada*, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990).

Desieno does not explicitly teach the particle distribution. However, it is well known in pharmaceutical art that the term "effective average particle" means at least 50% of the particle population. To be more significant, Liversidge teaches a dispersible particle made of a drug substance and a surface modifier adsorbed on the surface of the drug substance to maintain *an effective average particle size* of less than about 400 nm (abstract). The term "effective average particle size" is defined by Liversidge as at least 90% of the particle have an average particle size of less than 400 nm measured by using the technique that is so well known in pharmaceutical art (column 5, lines 20-39).

Desieno does not expressly teach the concentration of the rate-controlling polymer as well as the specific rate-controlling polymer claimed in claims 11 and 12, the binder and the lubricant claimed in claims 5-7.

Friend teaches a tablet dosage form made of matrix composed of drug dispersed in hydrocolloid and excipients (abstract, and column 5, lines 49-53). The excipients, such as binders, diluents, and lubricants are present at a level of from about 2-50% (column 11, lines 22-65). The excipients further include HPMC, PVP, and cellulosic derivatives (column 12, lines 1-33). Suitable lubricant, such as magnesium stearate are mixed with the drug substance and HPMC and then compressed into tablet (column 17, lines 56-61). The tablet is further coated using enteric coating polymers selected from cellulose acetate phthalate, polyvinyl acetate phthalate, methacrylic acid, and those polymers having the trade name Eudragit in an amount of from about 0.5 to about 10% (column 14, lines 20-62). Thus, it would have been obvious for one of ordinary skill in the art to modify the nanoparticle of Desieno and Liversidge using the excipients and the enteric coating polymers in an effective amount in view of the teachings of Friend, because Friend teaches a tablet dosage form suitable for controlled release of poorly soluble drug substance. The expected result would a controlled release film matrix coated carrier that exhibits excellent bioavailability and extremely stable.

It is noted at column 14, lines 7-10, the inner composition which makes up the matrix of the tablet is free of any enteric polymeric material. However, the claims of the present invention do not exclude coating the rate controlling polymer on the surface

nanoparticulate drug composition as taught by Friend and evidenced by applicants' claim 1 and 15.

Response to Arguments

Applicant's arguments filed 08/23/06 have been fully considered but they are not persuasive.

Applicant argues that the PVP/PEG overcoat taught by Desieno is not a rate-controlling polymer. However, the examiner is unable to determine the patentability distinct between the claimed PVP/PEG coat and the PVP/PEG over coat taught by Desieno. It is noted that products of identical chemical composition cannot have mutually exclusive properties. A chemical composition and its properties are inseparable. Therefore, if the prior art teaches the identical chemical structure, *the properties applicant discloses and/or claims are necessarily present*. *In re Spada*, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990).

Applicant argues that Desieno teaches that the overcoat does not inhibit re-dispersion of the drug in aqueous media, and therefore, applicant concludes Desieno teaches a rapid release composition. However, applicant is invited to submit data showing that the composition taught by Desieno with the overcoat comprising the claimed polymer would have a release rate that is outside the claimed release rate. Although Desieno teaches the overcoat does not inhibit redispersion of the drug in aqueous media, nowhere in Desieno indicates that the drug is release rapidly.

Applicant argues that the choice of a rate controlling polymer first depends upon the type of controlled release system to be utilized. A rate controlling composition

utilizing a coating system employs a polymer that forms a water insoluble backbone, such as poly(alkylmethacrylate), as a rate controlling polymer. Low molecular weight water-soluble polymers of PVP and PEG, can also be used in coating system, but in this context they must be used in conjunction with a polymer that forms a water insoluble backbone to yield a controlled release composition. Thus, if low molecular weight water-soluble polymers PVP and PEG are utilized in a coating system in the absence of a polymer that forms a water insoluble backbone, the resulting composition is an immediate release composition, such as that described by Desieno. In response to applicant's argument that the reference does not show certain features of applicant's invention, it is noted that the features upon which applicant relies (i.e., low molecular weight water-soluble polymers of PVP and PEG, in conjunction with a polymer that forms a water insoluble backbone to yield a controlled release composition) are not recited in the rejected claim. Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993).

Applicant argues that there is no motivation to combine Desieno in view of Liversidge and Friend. To clarify the record, the 103(a) rejection uses Desieno as a primary reference, in view of Liversidge and Friend. In response to applicant's argument that there is no suggestion to combine the references, the examiner recognizes that obviousness can only be established by combining or modifying the teachings of the prior art to produce the claimed invention where there is some teaching, suggestion, or motivation to do so found either in the references themselves

or in the knowledge generally available to one of ordinary skill in the art. See *In re Fine*, 837 F.2d 1071, 5 USPQ2d 1596 (Fed. Cir. 1988) and *In re Jones*, 958 F.2d 347, 21 USPQ2d 1941 (Fed. Cir. 1992). In this case, Liversidge is cited solely for the teaching of particle distribution and the meaning of "effective average particle size". Friend is cited solely for the teaching of the concentration of the rate-controlling polymer as well as the specific rate-controlling polymer claimed in claims 11 and 12, the binder and the lubricant claimed in claims 5-7. The test for obviousness is not whether the features of a secondary reference may be bodily incorporated into the structure of the primary reference; nor is it that the claimed invention must be expressly suggested in any one or all of the references. Rather, the test is what the combined teachings of the references would have suggested to those of ordinary skill in the art. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981).

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of

the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Susan T. Tran whose telephone number is (571) 272-0606. The examiner can normally be reached on M-F 6:00 am to 4:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward can be reached on (571) 272-8373. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



S. Tran
Patent Examiner
AU 1615